Table of Contents

• What is Cabazitaxel?
• How Cabazitaxel Works
• Conditions Treated with Cabazitaxel
• How Cabazitaxel is Administered
• Side Effects and Safety Considerations
• Ongoing Research and Future Prospects

What is Cabazitaxel?

Cabazitaxel is a novel cancer chemotherapy drug that belongs to the taxane class of medications. It is also known by its brand name Jevtana^[1]. Other names for this drug include XRP6258 and RPR116258A^[2]. Cabazitaxel is a semi-synthetic taxoid, which means it is derived from natural sources but has been chemically modified to enhance its effectiveness^[1].

How Cabazitaxel Works

Cabazitaxel works by binding to and stabilizing tubulin structures in cells. Tubulin is a protein that forms microtubules, which are essential for cell division. By stabilizing these structures, Cabazitaxel prevents the breakdown of microtubules, which in turn inhibits cell division and tumor cell proliferation^[1].

What makes Cabazitaxel unique among taxanes is its low affinity for a protein called P-glycoprotein. This protein is a drug efflux pump, which means it can remove certain drugs from cells. Many cancer cells produce high levels of P-glycoprotein, which can lead to resistance to traditional taxane drugs. Cabazitaxel’s low affinity for P-glycoprotein may allow it to overcome this resistance mechanism^[1].

Conditions Treated with Cabazitaxel

Cabazitaxel is primarily used to treat several types of cancer:

• Prostate Cancer: Cabazitaxel is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously been treated with a docetaxel-containing regimen^[3]. Metastatic means the cancer has spread to other parts of the body, and castration-resistant means the cancer continues to grow even when the level of testosterone is reduced to very low levels.
• Urothelial Carcinoma: This is a type of bladder cancer. Cabazitaxel is being studied as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma who have progressed after platinum-based chemotherapy^[4].
• Head and Neck Cancer: Research is ongoing to evaluate the effectiveness of Cabazitaxel in treating recurrent or metastatic head and neck cancer in patients who have not responded to other treatments^[5].
• Gastroesophageal Cancer: Studies are being conducted to assess the effectiveness of Cabazitaxel in patients with advanced gastroesophageal cancer who have progressed after at least one line of chemotherapy^[1].

How Cabazitaxel is Administered

Cabazitaxel is typically administered as an intravenous (IV) infusion. The standard dose is usually 25 mg/m² (milligrams per square meter of body surface area) given over one hour every 21 days^[4]. However, the exact dosage and schedule may vary depending on the specific condition being treated and the patient’s individual factors.

Before receiving Cabazitaxel, patients are usually given premedications to help prevent allergic reactions and other side effects. These may include:

• Antihistamines (such as dexchlorpheniramine or diphenhydramine)
• Corticosteroids (such as dexamethasone)
• H2 antagonists (such as ranitidine)
• Anti-nausea medications (such as ondansetron)^[6]

In some cases, Cabazitaxel may be given along with other medications. For example, in prostate cancer treatment, it is often combined with prednisone, a steroid medication that helps reduce inflammation and other symptoms^[3].

Side Effects and Safety Considerations

Like all chemotherapy drugs, Cabazitaxel can cause side effects. Some of the most common and significant side effects include:

• Neutropenia: This is a decrease in white blood cells called neutrophils, which can increase the risk of infections. It is one of the most common and serious side effects of Cabazitaxel^[6].
• Febrile Neutropenia: This is a condition where a patient with neutropenia develops a fever, indicating a possible infection^[7].
• Diarrhea: This can be severe in some cases and may require treatment^[7].
• Fatigue: Many patients experience tiredness or weakness during treatment.
• Nausea and Vomiting: These are common side effects of many chemotherapy drugs, including Cabazitaxel.

To help manage these side effects, especially neutropenia, doctors may prescribe medications called granulocyte-colony stimulating factors (G-CSF). These drugs help stimulate the production of white blood cells^[6].

Ongoing Research and Future Prospects

Researchers continue to study Cabazitaxel to find new ways to use it effectively and safely. Some areas of ongoing research include:

• Neoadjuvant Treatment: Studies are looking at using Cabazitaxel before surgery (neoadjuvant therapy) in patients with high-risk prostate cancer^[2].
• Combination Therapies: Researchers are investigating how Cabazitaxel works when combined with other treatments, such as hormonal therapy for prostate cancer^[2].
• Biomarkers: Scientists are trying to identify biological markers that could help predict which patients are most likely to benefit from Cabazitaxel treatment^[8].
• Quality of Life: Studies are assessing how Cabazitaxel treatment affects patients’ quality of life compared to other treatments^[2].

As research continues, our understanding of how to use Cabazitaxel most effectively will likely improve, potentially leading to better outcomes for patients with various types of cancer.